CXCL3 is a Potential Target for Breast Cancer Metastasis

ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)


Volume 14, 9 Issues, 2014


Download PDF Flyer




Current Cancer Drug Targets

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 54th of 197 in Oncology

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Ruiwen Zhang
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 4.00
5 - Year: 4.412

CXCL3 is a Potential Target for Breast Cancer Metastasis

Author(s): Amanda Lay Pin See, Poh Kuan Chong, Ssu-Yi Lu and Yoon Pin Lim

Affiliation: Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, MD6, Centre for Translational Medicine #10-01M, 14 Medical Drive, Singapore 117599.

Abstract

Secreted proteins are an attractive minefield for cancer drug targets. An iTRAQ-based tandem mass spectrometry approach was employed to relatively quantify proteins in the secretomes of four isogenic breast cancer cell lines with increasing metastatic potential. CXCL3 was found to be upregulated in aggressive cancer cells. SiRNA and antibody neutralization studies supported a role of CXCL3 in metastatic processes. Meta-analysis of the mRNA level of CXCL3 in 1881 breast tumors supported a role of CXCL3 in clinical breast cancer. Our results support a functional role of CXCL3 in breast cancer metastasis and as a viable target for cancer therapy.

Keywords: Breast cancer, chemokine, CXCL3, migration, proteomics, secretome.

Purchase Online Rights and Permissions

Article Details

Volume: 14
Issue Number: 3
First Page: 294
Last Page: 309
Page Count: 16
DOI: 10.2174/1568009614666140305222328
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science